Changing cholesterol levels: past, present, and future

Where are we now with changing cholesterol levels to reduce cardiovascular disease risk? Keith Fox (British Cardiovascular Society president) asks Rory Collins (professor of Medicine and Epidemiology and co-director of the Clinical Trial Service, Nuffield Department of Clinical Medicine, University of Oxford).

Professor Collins talks about the evidence behind altering high- and low-density lipoproteins, why the issue of myopathy has been overstated, and our best treatment options now and for the future.

See also:

Webcasts from all the sessions at the British Cardiovascular Society Conference 2012 http://bit.ly/ZMGmUE